Kneu Health, a precision neurology platform specializing in Parkinson’s disease and dementia management, has announced the closing of a $5.6 million oversubscribed seed funding round. This funding was co-led by Oxford Science Enterprises and Cedars-Sinai, with additional contributions from Social Impact Enterprises, JIMCO, G.K. Goh Ventures, and SXSW London.
The financial support will be instrumental in accelerating Kneu’s growth in the United States, enabling the company to scale up its deployments for Parkinson’s and expand its commercial capabilities. And Kneu plans to publish critical outcome data and improve its dementia monitoring efforts. With this recent investment, Kneu’s total funding has now reached $11.2 million.
The rise of neurological disorders poses a significant public health challenge, with Parkinson’s disease being recognized as the fastest-growing neurological condition worldwide. Projections indicate that dementia cases could triple by the year 2050.
Within the US, many patients face prolonged waits of several months to see specialists, exacerbated by a shortage of neurologists that leaves healthcare systems struggling to meet the overwhelming demand. This situation has led to a care model that typically reacts too late, often after a patient’s condition has already deteriorated, rather than providing the ongoing support that patients and their families require.
Kneu’s technological framework is grounded in more than a decade of longitudinal research. The platform has harnessed over 500,000 digital measures from more than 1,400 users across deployments in the NHS and the U.S. Its clinically trained AI models skillfully analyze a variety of metrics, including speech, movement, and cognitive function, to generate predictive biomarkers. These biomarkers help stratify risk among different populations and inform targeted interventions to improve patient outcomes.
Kneu has received FDA clearance for its smartphone-based tremor measurement, further validating the platform’s clinical rigor and allowing proactive monitoring to be seamlessly integrated into patients’ daily lives and care pathways.
Clinicians using Kneu’s platform have reported enhanced patient care experiences, with 67% of cases benefiting from faster-than-standard access to necessary treatments. Data-driven insights from the technology have also informed medication adjustments for over half of the patients, driving more effective treatment plans. And patients have reported up to a 30% improvement in their knowledge, confidence, and ability to manage their health, resulting in increased independence in their daily activities.
Pilot programs within the NHS have demonstrated that Kneu’s platform can boost operational efficiency by 30%, reduce emergency admissions, and shift the nature of Parkinson’s care from a reactive approach to a proactive, planned strategy. These improvements translate to significant healthcare savings, such as conserving 1,000 bed days for a single provider.
With contracts initiated at reputable institutions like Cedars-Sinai and Mass General Brigham, coupled with participation in the Global Incubator Programme at the Texas Medical Center Innovation (TMCi), Kneu has solidified its presence in some of the most influential medical ecosystems in America. These developments indicate a critical evolution in neurology: moving away from episodic care and instead placing continuous data at the heart of healthcare operations. Kneu is leading the charge in this transformation, showcasing the potential for better, more proactive neurology care through innovative technology.
KEY QUOTES:
“We’ve spent the last two years proving that remote monitoring can transform neurological care. Clinicians are getting clearer insight without added workload, patients no longer face months of uncertainty between visits, and gain confidence that changes will be recognized rather than missed. This funding allows us to bring that model to the U.S. at the right moment, when health systems are ready to move beyond band-aid solutions and embrace continuous neurological care as core infrastructure, accessible to anyone with a smartphone.”
Caroline Cake, co-founder and CEO, Kneu Health
“Neurology has had plenty of algorithms. What it has lacked is longitudinal signal that clinicians can trust and act on inside real workflows. Kneu has turned everyday phone interactions into a clinically governed measurement layer that scales across populations without new hardware or staffing. With evidence emerging on both sides of the Atlantic, Kneu is laying the foundation for a reference dataset and operating platform in Parkinson’s and dementia that raises standards of care while finally making the economics work for hospitals and payers.”
Joel Schoppig, Health Tech Investment Principal, Oxford Science Enterprises
“The strength of Kneu’s approach is how rigorous science is carried through into day-to-day practice. By giving neurologists longitudinal signal between visits, the platform reduces avoidable appointments and sharpens focus on the cases that matter most. This is the kind of clinically governed infrastructure we look for, and it is why we chose to back Kneu and bring it into our ecosystem.”
Nirdesh Gupta, Managing Director, Cedars-Sinai Technology Ventures
